Recent guidelines support the use of blood-based biomarkers (BBMs) in diagnosing Alzheimer's disease among cognitively impaired patients. With minimum thresholds for sensitivity and specificity established, these tests can serve as triaging or confirmatory tools based on a systematic review of 49 studies. The research examined biomarkers like plasma phosphorylated tau and Aβ42/Aβ40 ratio against established reference standards. However, the certainty of evidence is low, urging clinicians to consider pretest probabilities and comprehensive evaluations before utilizing BBMs in diagnostics.

Source: Alzheimer's & Dementia